lapatinib has been researched along with Dermatoses in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T | 1 |
Schwartz, J | 1 |
Frankel, C; Palmieri, FM | 1 |
Awada, A; Azim, HA; Metzger Filho, O; Saini, KS | 1 |
4 review(s) available for lapatinib and Dermatoses
Article | Year |
---|---|
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
Lapatinib side-effect management.
Topics: Antineoplastic Agents; Diarrhea; Humans; Lapatinib; Paronychia; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2010 |
Prevention and management of major side effects of targeted agents in breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast; Breast Neoplasms; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Skin Diseases; Trastuzumab | 2012 |
1 trial(s) available for lapatinib and Dermatoses
Article | Year |
---|---|
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Recurrence; Skin Diseases; Treatment Outcome | 2009 |